Potent Topoisomerase I Inhibition For Glioma Therapy

有效抑制拓扑异构酶 I 治疗神经胶质瘤

基本信息

  • 批准号:
    6337830
  • 负责人:
  • 金额:
    $ 13.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-05-01 至 2002-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (PROVIDED BY APPLICANT): DB-67 is a promising new silatecan (silylcamptothecin) analog that displays superior blood stability relative to the FDA-approved camptothecin congeners, topotecan and CPT- 11. DB-67 also exhibits a high degree of anti-cancer potency both in vitro and in vivo. DB-67 is a highly lipophilic camptothecin and active lactone levels persist in human tissues to a much greater degree than existing FDA-approved camptothecins. DB-67 has been shown by Pollack et al. to be more potent than other camptothecins against glioblastoma cells; in the same study the agent was found to be highly effective against intracranially implanted glioblastoma tumors. For this Phase I application there are two key issues that will be addressed. First, liposomal formulation studies are required as DB-67 is highly lipophilic and may crystallize at the site of injection unless properly formulated. Thus, we intend to develop a lyophilized liposomal DB-67 preparation that displays ideal stability and microemulsion characteristics upon re-suspension. Secondly, we will test our lead liposomal formulations in a human glioma xenograft murine model system to ensure that the DB-67 formulations exhibit the predicted efficacy profile. DB-67 has already been well explored in vitro and in vivo; thus, the intent of this Phase I application is to find the best formulation for advancing DB-67 to clinical trials by thoroughly studying various liposomal formulations. PROPOSED COMMERCIAL APPLICATION: Initial FDA approval of comptothecins (topotecan and CPT-11) occurred in 1996. In 1998 their use was expanded by the FDA for new indications. With other campthecins currently in clinical development, a worldwide market of approximately 1 billion dollars is anticipated in the near future. Our novel, blood-stable camptothecin, DB-67, described in this application may present several therapeutic advantages over the campthecin drugs that are currently used and, accordingly, could eventually control a significant portion of the campthecin market.
描述(申请人提供):DB-67是一种很有前途的新型硅胶 (硅喜树碱)类似物,其血液稳定性优于 FDA批准的喜树碱同系物拓扑替康和CPT-11.DB-67也 在体外和体内都显示出高度的抗癌效力。DB-67是 高亲脂性喜树碱和活性内酯水平在人体组织中持续存在 比现有FDA批准的喜树碱程度要高得多。DB-67具有 已由波拉克等人展示。比其他喜树碱更有效地对抗 胶质母细胞瘤细胞;在同一项研究中,该药物被发现非常有效 抗脑内植入的胶质母细胞瘤。对于此阶段I应用程序 有两个关键问题将得到解决。第一,脂质体制剂 需要进行研究,因为DB-67是高度亲油的,可能会在 注射部位,除非配方正确。因此,我们打算开发一种 具有理想稳定性和稳定性的冻干脂质体DB-67制剂 复悬浮液的微乳特性。其次,我们将测试我们的 人脑胶质瘤小鼠移植瘤模型系统中的脂质体制剂 确保DB-67配方表现出预期的功效概况。 DB-67已经在体外和体内得到了很好的探索;因此, 这一阶段的应用是寻找最佳配方,将DB-67推进到 通过深入研究各种脂质体配方进行临床试验。 建议的商业应用: FDA最初批准Comtothecins(拓扑替康和CPT-11)是在1996年。在……里面 1998年,FDA扩大了它们的使用范围,以适应新的适应症。与其他Campthecin 目前处于临床开发阶段,全球市场规模约为10亿美元 预计在不久的将来。我们的新型血液稳定喜树碱DB-67被描述为 在这一应用中可能呈现出比Campthecin药物更多的治疗优势 目前正在使用的,因此最终可能控制很大一部分 坎普特林市场。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.
C.B-17 SCID 小鼠中非脂质体 DB-67 和脂质体 DB-67 的血浆和组织分布。
  • DOI:
    10.1007/s10637-007-9109-9
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Zamboni,WilliamC;Jung,LauraL;Strychor,Sandra;Joseph,Erin;Zamboni,BethA;Fetterman,SarahA;Sidone,BrianJ;Burke,ThomasG;Curran,DennisP;Eiseman,JulieL
  • 通讯作者:
    Eiseman,JulieL
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS G BURKE其他文献

THOMAS G BURKE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS G BURKE', 18)}}的其他基金

PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6978297
  • 财政年份:
    2004
  • 资助金额:
    $ 13.31万
  • 项目类别:
Combinatorial Development of Blood Stable Camptothecins
血液稳定性喜树碱的组合开发
  • 批准号:
    6333194
  • 财政年份:
    2001
  • 资助金额:
    $ 13.31万
  • 项目类别:
FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN
抗癌药物拓扑替康的荧光检测
  • 批准号:
    6444723
  • 财政年份:
    2001
  • 资助金额:
    $ 13.31万
  • 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6444722
  • 财政年份:
    2001
  • 资助金额:
    $ 13.31万
  • 项目类别:
FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN
抗癌药物拓扑替康的荧光检测
  • 批准号:
    6315389
  • 财政年份:
    2000
  • 资助金额:
    $ 13.31万
  • 项目类别:
1 & 2 PHOTON FLUORESCENCE IMAGE CAMPTOTHECIN ANTICANCER DRUGS & DRUG CARRIERS
1
  • 批准号:
    6308191
  • 财政年份:
    2000
  • 资助金额:
    $ 13.31万
  • 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6315388
  • 财政年份:
    2000
  • 资助金额:
    $ 13.31万
  • 项目类别:
COMBINATORIAL DEVELOPMENT OF ANTICANCER SILATECANS
抗癌 SILATECANS 的联合开发
  • 批准号:
    6014855
  • 财政年份:
    2000
  • 资助金额:
    $ 13.31万
  • 项目类别:
PHOTON FLUORESCENCE IMAGE:CAMPTOTHECIN ANTICANCER DRUGS & CARRIER AT TUMOR SITES
光子荧光图像:喜树碱抗癌药物
  • 批准号:
    6220407
  • 财政年份:
    1999
  • 资助金额:
    $ 13.31万
  • 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6122885
  • 财政年份:
    1999
  • 资助金额:
    $ 13.31万
  • 项目类别:

相似海外基金

Self-Assembling Camptothecin Nanofiber Hydrogels as Adjunct Therapy for Intraoperative Treatment of Malignant Glioma
自组装喜树碱纳米纤维水凝胶作为恶性胶质瘤术中治疗的辅助疗法
  • 批准号:
    10738545
  • 财政年份:
    2023
  • 资助金额:
    $ 13.31万
  • 项目类别:
Synthesis and modification of intermediates in the camptothecin biosynthetic pathway
喜树碱生物合成途径中间体的合成与修饰
  • 批准号:
    576453-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.31万
  • 项目类别:
    Canadian Graduate Scholarships Foreign Study Supplements
Linking metabolic engineering with gene discovery towards biotechnological camptothecin production
将代谢工程与基因发现联系起来,以实现生物技术喜树碱生产
  • 批准号:
    571673-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 13.31万
  • 项目类别:
    Alliance Grants
Engineering cytochrome p450s for the production of hydroxylated camptothecin derivatives
工程化细胞色素 p450 用于生产羟基化喜树碱衍生物
  • 批准号:
    575889-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.31万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
An integrated approach to camptothecin biosynthesis discovery and engineering
喜树碱生物合成发现和工程的综合方法
  • 批准号:
    RGPIN-2019-05473
  • 财政年份:
    2022
  • 资助金额:
    $ 13.31万
  • 项目类别:
    Discovery Grants Program - Individual
An integrated approach to camptothecin biosynthesis discovery and engineering
喜树碱生物合成发现和工程的综合方法
  • 批准号:
    RGPIN-2019-05473
  • 财政年份:
    2021
  • 资助金额:
    $ 13.31万
  • 项目类别:
    Discovery Grants Program - Individual
Generation of camptothecin structural diversity via biocatalysts
通过生物催化剂产生喜树碱结构多样性
  • 批准号:
    560578-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 13.31万
  • 项目类别:
    University Undergraduate Student Research Awards
An integrated approach to camptothecin biosynthesis discovery and engineering
喜树碱生物合成发现和工程的综合方法
  • 批准号:
    RGPIN-2019-05473
  • 财政年份:
    2020
  • 资助金额:
    $ 13.31万
  • 项目类别:
    Discovery Grants Program - Individual
Investigation of the camptothecin biosynthetic pathway in Fusarium solanii
茄病镰刀菌喜树碱生物合成途径的研究
  • 批准号:
    553040-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 13.31万
  • 项目类别:
    University Undergraduate Student Research Awards
Systems biology approach to unravel biosynthesis and evolution of camptothecin, a potent anti-cancer natural product
系统生物学方法揭示喜树碱(一种有效的抗癌天然产物)的生物合成和进化
  • 批准号:
    19K16391
  • 财政年份:
    2019
  • 资助金额:
    $ 13.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了